Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01468168 · ClinicalTrials.gov registry record · Phase 2
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase 2 study, sponsored by Santen.
- Completed
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
NCT01468168 is a Phase 2 study that has completed, run by Santen. The registered enrollment target is 183 participants.
The verdict
NCT01468168, a Phase 2 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
Study Summary
To investigate the safety and efficacy of DE-101 to improve the signs and symptoms in dry-eye disease.
Interventions
- DRUG DE-101 Ophthalmic Suspension
- DRUG DE-101 Ophthalmic Suspension Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01468168
The ClinicalTrials.gov registry entry for NCT01468168 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DE-101 Ophthalmic Suspension is the first listed.
NCT01468168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01468168 about?
NCT01468168 is a clinical study titled "A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients". To investigate the safety and efficacy of DE-101 to improve the signs and symptoms in dry-eye disease.
What is the current status of trial NCT01468168?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2011-10. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01468168?
The interventions under investigation include: DE-101 Ophthalmic Suspension (DRUG), DE-101 Ophthalmic Suspension Vehicle (DRUG).
Who is sponsoring clinical trial NCT01468168?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.